Linnea R. Thorlacius
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II.
Journal: Dermatology and therapy
Published: February 15, 2026
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.
Journal: JAMA dermatology
Published: November 26, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.
Journal: Dermatology and therapy
Published: April 09, 2025
The HIdradenitis suppurativa DrainagE (HIDE) scale: development and content validation of a patient reported outcome measure.
Journal: The British journal of dermatology
Published: December 13, 2024
Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data.
Journal: Dermatology and therapy
Published: December 03, 2024
Moving forward in hidradenitis suppurativa lesion definitions and counts.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 15, 2024
Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus.
Journal: Journal of the American Academy of Dermatology
Published: June 11, 2024
Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
Journal: The British journal of dermatology
Published: May 24, 2024
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups.
Journal: Archives of dermatological research
Published: December 04, 2023
Clinical relevance and uptake of core outcome sets in dermatology.
Journal: Archives of dermatological research
Published: December 04, 2023
Severity rating of specific skin lesions in hidradenitis suppurativa: the ptient perspective.
Journal: The British journal of dermatology
Published: October 27, 2023
Last Updated: 09/26/2026